Metabolic engineering study demonstrates high-yield L-fucose synthesis in an engineered microbial platform, highlighting a sustainable and antibiotic-free route for industrial biomanufacturing.
l -Fucose, a functional monosaccharide with high commercial potential in pharmaceuticals, nutraceuticals, and cosmetics, can be efficiently produced via microbial synthesis. This study established a robust l -fucose production platform through a comprehensive genomic integration and pathway optimization. Key GDP- l -fucose biosynthetic genes were chromosomally integrated with optimized constitutive synthetic promoters, enhancing the precursor supply and yielding 6.47 g/L l -fucose. Copy number amplification of the α1,2-fucosyltransferase gene (BKHT) further improved flux through the “GDP- l -fucose → 2′-FL → l -fucose” pathway. Crucially, growth-phase-dependent expression of α- l -fucosidase ( afcA ) using the stationary-phase promoter alleviated metabolic burden, boosting titer to 15.37 g/L. Combinatorial cofactor engineering prioritized biomass formation, while fed-batch fermentation with delayed lactose induction achieved 86.58 g/L l -fucose in 95 h─without plasmids, inducers, or antibiotics. This integrated strategy establishes a scalable industrial process for sustainable l -fucose biomanufacturing.
No takes yet. Share an insight, caveat, or question.
Meng et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: